Mainstream Renewable Power Appoints Morten Henriksen as CEO
FORNEBU, Norway, Feb. 27, 2025 /PRNewswire/ -- The Board of Mainstream Renewable Power ("Mainstream"), the pureplay global wind and solar company majority-owned by Aker Horizons ASA, is pleased to announce the appointment of Morten Henriksen as Group CEO, effective April 1, 2025. Henriksen comes from the position of CEO of Gassnova, the Norwegian state enterprise for carbon capture and storage. His previous experience spans executive management roles in the energy industry in Norway and internationally for companies including Arendals Fossekompani and Statkraft, in addition to multiple board positions.
Current CEO Mary Quaney will continue to support Mainstream and the transition in a Senior Advisor capacity before stepping down in the second half of 2025 to pursue other interests.
The appointment comes as the Company implements its updated strategy, continuing to deliver significant cost base reduction targets and sharpening its focus on three core growth markets where it sees the greatest potential for value creation – South Africa, Australia, and the Philippines.
In order to reduce costs and leverage the resources of its majority shareholder Aker Horizons, Mainstream is relocating its headquarters from Dublin to Oslo in the first half of 2025. This is in line with its plan to reduce its cost base by approximately 65% by 2026, relative to 2023 levels.
Mainstream's Chairman, Kristian Røkke, said: "We would like to express our gratitude to Mary for her leadership over the last five years. She has guided Mainstream's global team with focus, resilience and integrity, navigating a period of industry-wide transformation."
He continued: "As we enter a new phase, Morten brings extensive experience and deep sector expertise to position Mainstream for growth. His leadership will be instrumental in executing the Company's strategy and driving Mainstream's growth in the global energy market."
Commenting on his appointment, Morten Henriksen said: "Mainstream is well positioned for the opportunities ahead. I am very excited about implementing our vision to build a lean and focused renewable energy company, leading in our core markets and creating value through strong project execution, a lean cost base and capital efficiency."
For further information, please contact:Jonas Gamre, Investor Relations, tel: +47 97 11 82 92,email: jonas.gamre@akerhorizons.comMats Ektvedt, Media, tel: +47 41 42 33 28,email: mats.ektvedt@corporatecommunications.no
About Aker Horizons
Aker Horizons develops green energy and green industry to accelerate the transition to Net Zero. The company is active in renewable energy, carbon capture and sustainable industrial assets. As part of the Aker group, Aker Horizons applies industrial, technological and capital markets expertise with a planet-positive purpose to drive decarbonization globally. Aker Horizons is listed on the Oslo Stock Exchange and headquartered in Fornebu, Norway. Across its portfolio, the company is present on five continents. www.akerhorizons.com
About Mainstream Renewable Power
Mainstream Renewable Power is a leading pure-play renewable energy company with wind and solar assets across Europe, Latin America, Africa, and Asia-Pacific. Mainstream is one of the most successful developers of gigawatt-scale renewables platforms, across onshore wind, offshore wind, and solar power generation. The company has successfully delivered 6.6 GW of wind and solar generation assets to financial close-ready and has a global project portfolio of 22.7 GW. www.mainstreamrp.com
This information was brought to you by Cision http://news.cision.com.
https://news.cision.com/aker-horizons/r/mainstream-renewable-power-appoints-morten-henriksen-as-ceo,c4111882
View original content:https://www.prnewswire.co.uk/news-releases/mainstream-renewable-power-appoints-morten-henriksen-as-ceo-302387515.html
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Engineering the Perfect Shower Squeegee: The Story Behind dancemoon JustHang Squeegee
NEW YORK, June 7, 2025 /PRNewswire/ -- dancemoon, the trailblazer in home cleaning innovation, proudly introduced its first-ever bathroom cleaning tool: the JustHang Squeegee. Designed for effortless use and stylish storage, the product officially launched worldwide on June 3 via dancemoon's website and Amazon, debuting at a special launch price of $19.99. It has been well-received on social media for its outstanding performance and uniquely innovative built-in hook, and has continued to gain traction on Amazon and the official website since its initial launch. What sets the JustHang Squeegee apart is the thoughtful design, inspired by the simple and universal natural habit of hanging things up after use. Through rounds of real-life testing and countless small tweaks, the dancemoon team turned this everyday habit into a clean, minimalist solution that blends form and function. And behind this seemingly simple tool is a deliberate design process worth sharing. How It's Made: Integrated Molded Structure: The built-in hook of JustHang Squeegee isn't a traditional after-assembly attachment. Instead, it is molded by one-piece injection molding. This process reduces breakage risk at joints, maintains minimalist lines and structural stability, prevents dirt buildup and avoids discoloration over time. The handle uses glass fiber reinforced PA66 and the scraper blade is made of hardened 45 steel, offering excellent strength and heat resistance, enabling JustHang Squeegee to withstand up to 75kg pressure without breaking. Size and Angle Validation: Based on user habit research, dancemoon designers analyzed common hanging points and user behaviors in the bathroom. Through multiple prototype tests and hanging simulations, the size and angle of the built-in hook were finely adjusted to ensure that it can be firmly fixed in places such as towel bars, glass doors and countertops, and perfectly fit the user's natural "use and hang" action. Premium Flexible Silicone: Made from high-elasticity 50 Shore A silicone, this material offers an ideal balance of flexibility and structural strength. After extensive durability testing, the dancemoon design team selected this specific hardness for its outstanding performance in wet and slippery environments, resisting deformation and cracking even with prolonged use. The result is a smoother, more efficient water-wiping experience and a significantly longer lifespan compared to traditional squeegees. Why JustHang Squeegee? Convenience: Effortless to hang anywhere even with wet hands. Versatility: Designed to fit seamlessly into various home settings, offering clean, clutter-free storage. Durability: One-piece molded construction minimizes breakage and lasts longer than traditional scrapers. To place an order, please visit dancemoon's Amazon store and Shopify. Or follow dancemoon on social media to stay updated with the latest campaigns for the new product: Instagram: Facebook: YouTube: About dancemoon Driven by a passion for innovative design, dancemoon infuses the beauty and emotion of the moon into each product. Beyond offering household tools, dancemoon combines innovation with minimalist design to create products that make household tasks simple and no longer a burden but an enjoyable part of life. With a vision to become the leading brand of minimalist lifestyle, dancemoon is committed to blending minimalism with household tools, bringing bliss into your daily life. CONTACT: info@ View original content to download multimedia: SOURCE dancemoon
Yahoo
20 hours ago
- Yahoo
Prediction: in 12 months the dirt-cheap Shell share price could turn £10,000 into…
The Shell (LSE SHEL) share price looks cheap right now, with a price-to-earnings ratio of just 8.95. That's well below the average FTSE 100 P/E of 15 times. There's a reason for that, of course. Shell shares have fallen with the oil price, slumping almost 10% in 12 months. They're still up 67% over five years though. That's less than half the drop suffered by FTSE 100 rival BP. Shell seems to have a better idea how to navigate the push to net zero, but with the oil price hovering around $65 a barrel, it's still struggling. It's far from a done deal that Shell can bounce back from today's lows and make investors rich all over again. There is little sign the oil price is about to recover. With OPEC+ increasing production, it could fall further, especially as China struggles and Donald Trump brings volatility. Then there's the push towards net zero, which could go either way. Theoretically, building a new line of renewable energy will threaten fossil fuel behemoths, but we need them to help us push through the transition. This is particularly true given exponentially rising energy demand, thanks to AI and the rest. Shell's first-quarter results, published on 2 May, showed adjusted earnings of $5.6bn. That's a big drop from $7.73bn a year earlier but ahead of analyst expectations of $4.96bn. The company also announced another $3.5bn quarterly share buyback programme, marking the 14th consecutive quarter of at least $3bn in buybacks. Cash flow from operations came in at $9.3bn, slightly below consensus expectations of $9.6bn. So what about that dividend? A trailing yield of 4.4% is okay, but not exactly to die for. It's expected to creep up in 2026, but only to 4.49%. Shell isn't the dividend superstar it once was. Over the last 15 years, I would have expected shareholder payouts to compound at a decent clip. Instead, it's fallen by an average of 2.88% a year. The board didn't just slash its full-year dividend from 188 US cents in 2019 to 65.3 cents during the 2020 pandemic. It rebased it. While payouts have climbed at a decent clip since, they started from that lower level. In 2024, the total dividend was 139 US cents. That's at levels last seen in 2007. The 19 analysts serving up one-year share price forecasts have produced a median target of around 3,027p. If correct, that's a handsome increase of around 21.5% from today. Combined with that yield, this would give investors a total return of 26%. Based on that, if somebody invested £10,000 in the stock today, it would grow to £12,600 in a year. Obviously, nobody can predict the future like that. I use it only as a guide to market thinking. Here's another. Of the 32 analysts giving one-year stock ratings, an impressive 23 name Shell a Strong Buy. Four say Hold and five say Sell. Shell continues to face risks, as the oil price slows, net zero spreads confusion, and the global economy struggles. It may look cheap, but there's no guarantee its shares will suddenly close the valuation gap. But for those wanting exposure to energy, today's low valuation does make Shell worth considering. More so than BP, in my book. The post Prediction: in 12 months the dirt-cheap Shell share price could turn £10,000 into… appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Harvey Jones has positions in Bp P.l.c. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025
Yahoo
a day ago
- Yahoo
Nucleus Genomics Launches Nucleus Embryo, Genetic Optimization Software Alongside Partnership with Genomic Prediction
Parents pursuing IVF now have a new level of choice to empower their family planning NEW YORK, June 4, 2025 /PRNewswire/ -- With U.S. birthrates plummeting and IVF on the rise, Nucleus Genomics today launched Nucleus Embryo, the first genetic optimization software that lets parents see and understand a complete genetic profile to select an embryo. "Before there's a heartbeat, there's DNA," said Kian Sadeghi, founder and CEO of Nucleus. "One file containing DNA and genetic markers can tell you more about your baby's future than any other test a doctor could possibly run at this stage. Most clinics stop at whether an embryo will develop. For many parents, that's not enough. Patients have long asked for more transparency from clinics, and Nucleus Embryo is an important step toward complete data ownership for parents planning their families." The software enables parents to analyze and compare up to 20 embryos across over 900 hereditary conditions and 40 additional analyses beyond basic viability, spanning cancers, chronic conditions, appearance, cognitive ability, mental health, and more. To widen access to the software, Nucleus will partner with Genomic Prediction, the first company to offer genome-wide screening on embryos. The partnership sets a new standard in genetic medicine, continuing Genomic Prediction's decade-long history of giving hopeful parents the best possible chance of implanting healthy embryos. The company's analyses focus on hereditary conditions, acting as the first line of defense against chronic and rare diseases. "As an organization, we are committed to supporting patients' rights to their DNA and any information that can aid in their family-building journey," said Kelly Ketterson, CEO of Genomic Prediction. "We have a legacy of innovation aimed at providing patients with access to the best scientific resources. Our partnership with Nucleus opens access to information our patients have requested and allows us to uphold our commitment to this legacy." Nucleus' partnership with Genomic Prediction reflects a growing shift in how parents think about genetics as a tool to give children the best possible start in life. A wide-ranging study of Americans found the majority accepted the use of genetic technology to choose embryos based on health and personality traits. Four in 10 parents would use genetic optimization as another tool to understand their future child's cognitive abilities. Most women undergo three to six IVF cycles before successfully having a baby, with each cycle costing up to $25,000. Many embryos are unviable within days of being fertilized, leaving parents with few to choose from. Facing high stakes, clinicians often recommend genetic testing to optimize a couple's chances of a healthy pregnancy. But these tests typically stop at a select number of hereditary conditions and chromosome count. Now, advanced genetic analysis from Nucleus gives parents a new window into the health and well-being of their future child. Nucleus Embryo provides a comprehensive genetic profile for each embryo, encompassing hereditary genetic diseases, like cystic fibrosis and hemochromatosis, alongside genetic measures of cognitive ability, mental health, and risk for chronic diseases. Wide access to genetic insights for embryos can also help extend lifespan from the earliest stages of life. While more than half of all deaths annually in the U.S. are attributed to chronic, age-related conditions — such as Alzheimer's disease, diabetes, cancer, and heart disease — research shows embryonic selection can materially help reduce disease risk for these conditions. "We celebrate health optimization and the pursuit of longevity in every other part of life via our focus on training, supplements, and sleep," Sadeghi said. "We all know health isn't just the absence of disease. It's the ability to understand our bodies and genetic makeup to reach our full potential. Now we can apply this principle to life's inception." About Nucleus Genomics Nucleus builds software for generational health. Inspired by the loss of his cousin who died of a rare — yet preventable — genetic disease, Nucleus founder and Thiel Fellow Kian Sadeghi left an Ivy League university to build a product that could have saved her life. Our advanced DNA health test and analysis takes the guesswork out of your health, whether it's perfecting your protocols, knowing your risk for cancer, or planning for a healthy family. Follow us on social media @nucleusgenomics. About Genomic Prediction Genomic Prediction, Inc. is the frontrunner in advanced embryo screening. Our proprietary LifeView platform is state-of-the-art technology that assesses embryos for genetic health aimed at improved IVF outcomes. The LifeView Embryo Health Score Test (EHS) offers insight into the likelihood of developing conditions driven by multiple genes. It tests for significant health issues, including cardiovascular disease, diabetes mellitus, certain cancers, and mental health conditions. The EHS results are derived from the same embryo sample used in the following PGT tests: PGT-A: Identifies chromosome abnormalities in embryos. PGT-A+: Pinpoints the origin (paternal, maternal, or embryonic) of chromosome abnormalities. PGT-M: Decreases the chances of passing on monogenic (single-gene) conditions. PGT-SR: Detects chromosome abnormalities and structural imbalances, providing clarity between normal and balanced chromosomes. View original content to download multimedia: SOURCE Nucleus
